Prof. Dr. Selvakumar Subbian, PhD, joined the PHRI/NJMS as a Junior Research Faculty in 1998, promoted to Assistant Professor of Medicine in 2013, and to Associate Professor since 2018. He is an expert on the molecular immunologic studies of tuberculosis (TB) and COVID-19 and is well known for studies on the host-pathogen interactions using preclinical animal models in BSL3 settings, as evidenced by his publications. For the first time in literature, Dr. Subbian has reported the genome-wide transcriptome profiling of rabbit lungs with tuberculosis in 2011. Using preclinical studies, he provided proof-of-concept to a human clinical trial for the beneficial effect of a phosphodiesterase-4 inhibitor as host-directed therapy for TB. Over the years, Dr. Subbian’s research programs have been funded by several federal and private funding, and he has extensive collaboration network within and outside of Rutgers in preclinical evaluation, immunopathology, transcriptome-based biomarker discovery etc., in TB and COVID-19.
- Title
- Associate Professor
- Area of Study/Expertise
- Tuberculosis; Mycobacterium; Animal models of tuberculosis; Immunopathology of infectious diseases; Host directed therapy; Transcriptome analysis
- subbiase@njms.rutgers.edu